Quintiles Acquisition To Strengthen Its Tissue-Based Testing In Oncologic Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Newly acquired Targeted Molecular Diagnostics will become Quintiles’ oncology biomarker R&D center.
You may also be interested in...
ODAC to review KRAS biomarker
FDA's Oncologic Drugs Advisory Committee will meet Dec. 16 to discuss the use of the KRAS mutation status as predictive/prognostic biomarker to evaluate patients more likely to respond to ImClone's Erbitux (cetuximab) and Amgen's Vectibix (panitumumab). The biomarker was highlighted at a plenary presentation of the CRYSTAL study at ASCO (1Pharmaceutical Approvals Monthly, June 1, 2008, p. 16). European labeling for the EGFR inhibitors already limits use to patients with the KRAS wild-type gene
KRAS Mutation Effective Biomarker For Vectibix Success, Amgen Reports
Biotech adds to industry KRAS buzz with biomarker analysis from its “408” study of the anti-EGFR comparing effectiveness against wild-type and mutated tumors.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately-owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.